170 reports of this reaction
2.5% of all ROPIVACAINE HYDROCHLORIDE reports
#10 most reported adverse reaction
RESPIRATORY TRACT INFECTION is the #10 most commonly reported adverse reaction for ROPIVACAINE HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 170 FDA adverse event reports linking ROPIVACAINE HYDROCHLORIDE to RESPIRATORY TRACT INFECTION. This represents approximately 2.5% of all 6,839 adverse event reports for this drug.
Patients taking ROPIVACAINE HYDROCHLORIDE who experience respiratory tract infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RESPIRATORY TRACT INFECTION is a less commonly reported adverse event for ROPIVACAINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to respiratory tract infection, the following adverse reactions have been reported for ROPIVACAINE HYDROCHLORIDE:
The following drugs have also been linked to respiratory tract infection in FDA adverse event reports:
RESPIRATORY TRACT INFECTION has been reported as an adverse event in 170 FDA reports for ROPIVACAINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RESPIRATORY TRACT INFECTION accounts for approximately 2.5% of all adverse event reports for ROPIVACAINE HYDROCHLORIDE, making it a notable side effect.
If you experience respiratory tract infection while taking ROPIVACAINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.